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Abstract
Autologous tissue engineered vascular grafts (TEVGs) are limited by graft
stenosis. Small diameter TEVGs implanted as unseeded scaffolds are prone to failure by
occlusive luminal proliferation of smooth muscle cells derived from endothelial
precursors within a critical period of two weeks. The development, validation, and
application novel platform for controlling TEVG performance by local delivery of
peptide and/or small molecule therapeutic agents from the TEVG scaffold is presented
with insights into the autologous TEVG biology and development.
We hypothesized that inhibition of TGF-βR1 by local delivery of SB-431542, a
competitive inhibitor of ALK5/TGFβR1 signaling, is superior to systemic administration
of SB-431542 in the prevention of EndMT-mediated neointimal hyperplastic stenosis of a
TEVG during the critical period for graft failure in a mouse model. Specific aims
included the development of a multiplexed hybrid drug release platform for delivery of
small molecule and/or protein species from a TEVG scaffold; validation of the clinical
utility of local versus systemic delivery of SB-431542 in the prevention of TEVG
neointimal hyperplastic stenosis in a small animal model; and exploration of TGF-β1
signaling in EndMT and TEVG neointimal hyperplastic stenosis.
Local delivery of SB-431542 or recombinant human TGF-β1 prevented stenosis
of a small diameter TEVG. Optimization of the local delivery platform achieved
maximum therapeutic efficacy with lower costs than systemic therapy. TGF-β1 signaling
is central to endothelial-mesenchymal transition in TEVG dysfunction. Translation of this
technology for vascular interventional therapy the hypoplastic left heart syndrome has the
potential to improve clinical outcomes.
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Foreword
“Age was respected among his people, but achievement was revered. As the elders said,
if a child washed his hands he could eat with kings.”
― Chinua Achebe, Things Fall Apart

As a child, my first dream child was to be an inventor. The light and shoulders of those
who made this work possible have carried me toward the realization of that dream. A
testament to the clarity of their guidance and the power of our collective efforts is the
submission of this work as a component of:

Yale University, Breuer CK, Fahmy T, Simons M, Chen PY, Duncan DR,
Patterson JT. Compositions and method for treating and preventing neointimal
stenosis. International Patent Application No. PCT/US2012/40759. 6 December
2012.

My second, somewhat more specific, dream was to be an orthopaedic surgeon-scientist.
My intent with this project was always to acquire principles of tissue engineering for
application in that field. To continue down the avenue of research detailed herein – which
I believe to be a noble endeavor, and a great privilege to have scratched the surface of –
would have been to stray from my professional and personal ambitions. As the Breuer
research group left Yale for Ohio State University/Nationwide Children’s Hospital, I
apprehensively submitted an application for a Howard Hughes Medical Institute Medical
Research Fellowship to support an additional year engaged in more of this research, work
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very remotely related to my intended career path and geographically isolated from the
personal relationships that sustain me.

Subsequent clinic experiences in the third year of medical school made it exquisitely
clear which professional avenue would be the most fulfilling for me. I chose to decline
the HHMI award and complete medical school in four years. This was a choice that I
alone made and one that I may always question. I am grateful for the generosity and
understanding of those affected by my errant perfidy, and that a more deserving peer at
Yale received and made outstanding that fellowship support.

Shamefully absent from this thesis document are the would-be products of that
abandoned research year: the likely application of this system toward further
investigations of vascular tissue engineering and whatever may have followed.

Joseph Thomas Patterson
31 December 2013
New Haven, CT
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Introduction
Congenital heart disease in the United States
Congenital heart disease is both the most common and most lethal congenital
anomaly, affecting 1% of live births in the United States. The leading cause of death
among congenital anomalies in the newborn period, congenital heart disease accounts for
more pediatric deaths than all childhood cancers combined. Half of all infants born with
CHD require surgical intervention to establish cardiovascular continuity that can support
growth and prevent development of arrhythmias, developmental disorders, congestive
heart failure, and early death1.
Of the manifold forms of congenital heart disease, the univentricular physiologies
including hypoplastic left heart, tricuspid atresia, and pulmonary atresia represent the
most severe variety of congenital heart disease. The univentricular physiologies account
for the highest treated and untreated mortality as well as the highest treatment costs 2.
Untreated mortality ranges from 70-95% in the first year of life. Surgical correction, in
the form of staged palliative operations which moderately reduce mortality at substantial
economic, somatic, and neurocognitive costs, remains the gold standard of treatment for
these univentricular anomalies3.
The inadequacy of current care for these diseases warrants the devotion of
research resources to further characterization and the development of more effective
treatment solutions. Our group has chosen to focus on the most individually burdensome
and refractory of the single ventricle physiologies as the disease entity and patient
population that stand to reap the greatest gains from such efforts. Hypoplastic left heart
syndrome occurs in 0.162/1000 U.S. live births and accounts for only 4-8% of congenital
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heart disease1. Though one of the least common forms of congenital heart disease,
hypoplastic left heart syndrome continues to frustrate clinicians as the most lethal variant
of the univentricular physiologies as well as the most expensive type of congenital heart
disease to treat2,4.

Hypoplastic left heart-syndrome
The “hypoplastic left heart” describes a spectrum of left heart hypoplasia with no
single pathogenic etiology. The variable constellation of observed anomalies amount to a
physiologically inadequate cardiopulmonary system that precipitates universally fatal
ischemic congenital heart disease. Variable hypoplasia of the mitral valve, aortic valve,
and ascending aorta combined with fibroelastosis of the left ventricle render systemic
perfusion dependent upon a single hypofunctional ventricle. Simultaneous arteriovenous
mixing via both a patent ductus arteriosus and a nonrestrictive patent foramen ovale are
necessary to sustain life. Without treatment, physiologic postnatal ductal closure and
falling pulmonary vascular resistance precipitate hypoxemia, acidosis, and shock.
Untreated mortality exceeds 95% within the first month of life 5.
The popular mechanistic theory of the development of hypoplastic left heart
syndrome describes a primary isolated left-sided defect that disrupts load- or flowdependent fetal development of other left heart structures. In one example, critical aortic
stenosis in the second trimester leads to a normal-sized or dilated left ventricle, retrograde
flow across the transverse arch and foramen ovale, and monophasic mitral valve inflow
that progresses to left heart hypoplasia and univentricular physiology at birth 6. Genetic
associations with Patau, Edward, Turner, and Jacobsen syndromes, GJA1, NKX2-5,
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NOTCH1, and HAND1 mutations, and 10 loci of undetermined significance as well as
familial associations with bicuspid aortic valve speak to the heterogeneic etiologies of
hypoplastic left heart syndrome7. Environmental associations are unclear; in utero
organic solvent exposure has been recently questioned8.

Figure 1. Staged surgical correction of hypoplastic left heart syndrome, (A) Schematic
representation of anatomical defects comprising the hypoplastic left heart syndrome. (B)
Stage I Norwood procedure. (C) Stage I Hybrid alternative to Norwood procedure. (D,E)
Stage II Blalock-Taussig (D) or Sano shunt from right ventricle to right atrium. (F) Stage
III modified Fontan procedure with extracardiac shunt from inferior vena cava to right
pulmonary artery achieves total cavopolumonary connection. Reproduced with
permission from Wolters Kluwer Health (RightsLink license No. 3299370435539)5.
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State of current therapy
Surgical therapy is the mainstay of definitive treatment for hypoplastic left heart
syndrome. Five-year survival now approaches 65-77% after staged Norwood palliation9,10
and 76-84% after cardiac transplant11,12. However, mortality on the transplant waiting list
varies regionally from 20-40%13. The lack of appropriate cardiac donors has solidified
the position of staged palliative surgery as the standard of care our arsenal of treatments
for this disease3.
Treatment begins at birth with prostaglandin E 1 to maintain patency of the ductus
arteriosus and temporarily preserve systemic circulation. The surgical stage I, the
Norwood procedure, is typically performed within the first week of life. The pulmonary
artery and pulmonary valve are incorporated into the aortic arch, forcing the right
ventricle to assume the functional position of the hypoplastic left ventricle as the
physiologic driver of bloodflow to both the systemic and pulmonary circuits. An atrial
septostomy routes pulmonary venous return to the right ventricle. A Blalock-Taussig or
Sano shunt recirculates mixed venous return and oxygenated blood from the lungs to the
pulmonary arteries, enhancing the oxygen saturation of blood entering the systemic
circuit at the cost of increased dynamic load for the right ventricle. An alternative hybrid
approach to Stage I palliation involves ductal stenting, transcatheter atrial septoplasty,
and pulmonary artery banding. Hybrid stage I palliation and improved perioperative
management account for recent modest improvements in survival 3.
Stage II palliation is performed at 4-6 months of age. The aortic repair is
completed and a bidirectional Glenn shunt or hemi-Fontan shunt is installed to route
blood from the superior vena cava(s) directly to the pulmonary artery and unload the right
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atrium. The Blalock-Taussig or Sano shunt is taken down to unloads the right ventricle.
Stage II boosts arterial oxygen saturation to approximately 80%.
Stage III, the completion, modified, or hemi-Fontan procedure is performed at 2-4
years of age, when the diameter of the pediatric inferior vena is typically 60-80% that of
the adult IVC. This operation fully relieves cyanosis by routing the inferior vena cava to
the pulmonary arterial circulation with an adult-size (20-22 mm) vascular conduit. The
original Fontan, developed in the 1970s, directly connected the right atrium to the
pulmonary artery but the size mismatch between the IVC and atrium produced
nonlaminar blood flow from the IVC to the atrium and was associated with unacceptably
high rates of morbidity and mortality14,15. The modified Fontan most commonly
performed uses an extracardiac conduit to channel blood from the inferior vena cava
directly to the right pulmonary artery. This extracardiac total cavopulmonary connection
bypasses the right atrium, thus maintaining laminar flow and increasing the flow of blood
through the pulmonary circulation16. However, complications arising from the use of
synthetic vascular grafts are a leading source of morbidity and mortality17,18. No existing
vascular graft is an ideal conduit for the extracardiac total cavopulmonary connection.
Polytetrafluoroethylene (PTFE or Gore-Tex) conduits, which have a lower failure rate
than Dacron19, are currently the most widely used vascular grafts for this operation20.
Autografts are rarely used21.

Figure 2 (opposite). Gary Kopf, MD, and Toshiharu Shinoka, MD, implant the first tissue
engineered-vascular graft for the treatment of pediatric congenital heart disease in the
United States. 18 August 2012, New Haven, CT.
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Characterization of TEVGs in animal models

Figure 3. Proposed mechanism of TEVG formation. Reproduced with permission of
PNAS22.

Expanded autologous vascular cell lines were seeded onto biodegradable
scaffolds of tubularized polyglactin or 50:50 copolymer of L-lactide and -caprolactone
polywoven (PCLA) mesh sealed with nonwoven polyglycolic acid (PGA) mesh. Seeded
or unseeded constructs were implanted as interposition grafts replacing 2 cm sections of
the main pulmonary artery in juvenile lambs (polyglactin, N=8) or as thoracic IVC
interposition grafts in dogs (PCLA, N=4). At six months after implantation, all seeded
scaffolds were patent without anticoagulation, possessed an endothelial lining and overall
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morphology resembling native pulmonary artery, and demonstrated non-aneurysmal
increase in size. Conversely, unseeded scaffolds formed thrombi and stenosed within two
weeks of implantation23,24. These results highlighted the importance of cell seeding for
TEVG performance but did not elucidate the mechanism by which seeded cells affected
TEVG development.
Prior studies by other investigators had demonstrated that vascular grafts seeded
with bone marrow cells (BMCs) formed an endothelial monolayer25. Rapid
endothelization is desirable because healthy ECs reduce the immediate thrombogenicity
and immunogenicity of the TEVG and enhance long-term patency26 . Bone marrow also
contains

endothelial

progenitor

cells

(EPCs)

that

may

contribute

to

graft

endothelialization and that autocrine signals released by seeded BMCs contribute to
vasculogenesis and endothelialization25,27.
Autologous BMCs enriched for the mononuclear fraction (BM-MNCs) were
statically seeded on PCLA/PGA scaffolds, cultured for two hours, and implanted as
interposition grafts replacing the intra-thoracic IVC in an adult beagles (N=16). All
seeded grafts were patent up to two years without evidence of thrombosis, stenosis or
aneurysm formation. Seeded BM-MNCs adhered to the scaffold before implantation.
Autologous BM-MNCs could be used as a practical cell source for creating TEVGs,
enabling rapid cell harvest without the need for cell culture 28.
Further investigations were performed in a sub-1-mm TEVG mouse model that
recapitulates the development of its human and lamb counterparts on a more rapid time
scale29. When implanted as interposition grafts, these small diameter scaffolds undergo
an inflammatory cellularization and remodeling that yields vascular neotissue22. Lineage
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tracing studies revealed that endothelial and smooth cells migrate in from the adjacent
vessel to cover the lumen in concentric layers30 while circulating macrophages take up
residence between the scaffold fibers31. Seeding the bare scaffold with BM-MNCs before
implantation enhanced graft patency rates and accelerated macrophage and endothelial
cell infiltration. However, MRI tracking demonstrated that the seeded cells rapidly
departed the scaffold32. Seeded cells attracted and influenced the behavior of their
cellular successors via a paracrine mechanism involving the deposition of cytokines
MCP-1 and PDGF on the scaffold surface33.

Limitations of cell seeded scaffolds
Manufacturing fully autologous tissue outside of the patient before implantation is
expensive; such endeavors require a great deal of time, equipment, facilities, and
personnel, and are prone to defects and contamination throughout the fabrication period.
Ex-vivo expansion of fully differentiated autologous vascular cell lines can take weeks,
and is especially time consuming with tissues derived from patients with vascular disease
and other systemic illnesses. Even bone marrow-derived stem cells, which may be
harvested, processed, and seeded on a scaffold to create a Fontan conduit that is
implanted on the same day as harvesting, requires a large team of personnel and more
than eight hours of general anesthesia. Such limitations and challenges make the prospect
of an unseeded scaffold very alluring.
Cytokine release from unseeded TEVG scaffolds can modulate the host response
to an implanted TEVG to achieve a similar graft phenotype and patency rate as those
attained with cell seeded grafts22. This observation that cytokine signaling can substitute
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for cell seeding in TEVG formation encouraged our pursuit of a “cell-free approach” to
tissue engineering whereby scaffolds are modified to slowly release signals that direct
host cells to populate the initially acellular scaffold and form a desired architecture 34.

Cell-free paradigm: drug and cytokine release
Integration of a biomedically engineered drug delivery system with the wellstudied TEVG scaffold will be central to the fabrication vascular grafts that can control
the cellular and molecular processes responsible for neovessel formation. The patient
tissues become employees in the assembly line while the scaffold acts as a foreman and
blueprint and the cytokines function as instructions.
A cell-free TEVG will eliminate the need for biopsy, ex-vivo culture, and seeding
of recipient cells – existing challenges to clinical use of TEVG. This will render
autologous vessel or bone marrow harvest unnecessary and furnish drastic reductions in
economic, personnel, and facility requirements. Moreover, properly stored cytokineeluting vascular grafts may have shelf lives potentially comparable to PTFE and Dacron
grafts. Further characterization of the natural history of TEVG development will inform
the selection of cytokines with which to incorporate into scaffolds to improve TEVG
performance. The era of an off-the-shelf vascular graft that grows with the patient and
behaves like or better than a native vessel is in sight.
The questions, central to this thesis, then become: (a) what process(es) should be
targeted to improve TEVG performance; (b) what intervention(s) should be performed;
and (c) how can this be implemented without the harvesting of living cells or tissue?
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The target: TGF-β1 signaling in endothelial-mesenchymal transition

Figure 4. TGF-β signaling pathways in vascular endothelial cells. Reproduced with
permission from Elsevier (RightsLink License No. 3299370750146) 35.

TEVGs provide decreasing vascular resistance over time via neovessel growth,
but unregulated growth may become pathologic. The primary mode of TEVG failure in
humans and animals is luminal stenosis characterized by hyperplastic graft wall
thickening and vessel occlusion36,37. Excess TGF-β1 protein and mRNA are present in
stenosed and unseeded small diameter TEVGs. Our group demonstrated that TGF-β1driven endothelial-mesenchymal transition (EndMT) is the primary mechanism of TEVG
stenosis, which is the sole observed mechanism of TEVG dysfunction 38. Targeting the
EndMT process, then, would be the most logical way to improve TEVG clinical utility.
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EndMT is a subset of the epithelial-mesenchymal transition essential during
cardiac development and tissue regeneration that also underlies pathologic conditions
such as cardiac and hepatic fibrosis and several forms of cancer39. EndMT occurs when
endothelial cells and endothelial cell progenitors lose their cell junctions, delaminate
from the vessel lumen, and invade the underlying tissue. These cells exhibit loss of
endothelial markers (CD31, Pecam-1, VE-cadherin) and acquisition of mesenchymal
markers (SMA, N-cadherin)40. The EndMT process is essential during cardiac
development and tissue regeneration but also underlies pathologic conditions such as
cardiac and hepatic fibrosis and several forms of cancer 39.
Though its effects are concentration-dependent, TGF-β1 induces mouse
endothelial cells to undergo EndMT in vitro by signaling primarily through canonical
Smad activation and possibly via non-canonical MEK, PI3K, and p38 MAPK
pathways41,42. Activin receptor-like kinase 5 (ALK5) is the dominant mediator of TGF-β1
signaling in mouse endothelial cells: TGF-β1 → ALK5/ TGF-β1RII → Smad2/3
phosphorylation disrupts endothelial remodeling by suppressing expression of inhibitor
of differentiation-1 (Id1)43,44. Conversely, TGF-β/BMP → ALK1/TGF-β1RII → pSmad1/5 enhances vessel remodeling by upregulating Id1 and PAI-145. Pathway
dominance of ALK1 vs. ALK5 depends upon TGF-β1 concentration and duration of
exposure44. Though ALK1 activity in vitro elicits responses that are opposite those
observed with ALK5 stimulation, the relationship between ALK1 and ALK5 signaling
and subsequent endothelial cell behavior is complicated by ligand exposure time and
concentration, ALK1/ALK5 codimerization, lateral signaling, coreceptors, and
downstream crosstalk44.
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TGF-β1 type II receptors phosphorylate the polarity protein PAR6 which leads to
the disassembly of tight junctions46. c-Abl and PKC-δ kinases also appear critical for
TGF-β-mediated EndMT47. However, the effect of TGF-β1 concentration and exposure
time on EndMT in vivo is unknown. Endothelial and vascular smooth muscle cells
constitutively produce TGF-β1, and activation of these cells attenuates endogenous TGFβ1 production.
TGF-β1 promotes mouse endothelial cell proliferation and migration at low
concentrations but is inhibitory at high concentrations35. This paradox appears related to
both the intensity and duration of the signal as well as competition between parallel Smad
pathways. Activin receptor-like kinase 5 (ALK5) is the dominant type I TGF-β receptor
in endothelial cells; TGF-β11 → ALK5/ TGF-β1RII → Smad2/3 phosphorylation
suppresses expression of inhibitor of differentiation-1 (Id1) and obstructs angiogenesis by
inhibiting endothelial cell proliferation, migration, and organization. Though some
authors described this as an induced “quiescent state,” ALK5 → Smad2/3 signaling
disrupts endothelial remodeling43,44.

The intervention: SB-431542, a small-molecule ALK inhibitor
SB-431542 is a potent and specific but poorly soluble inhibitor of Alk5, the
dominant type I TGF-β receptor in endothelial cells48,49. D. R. Duncan and colleagues
demonstrated that systemic administration of this inhibitor in a mouse model of TEVG
formation prevents neointimal , mechanistically by inhibiting of endothelialmesenchymal cell transition38.
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Long-term administration of SB-431542 which has quantifiable activity at range
of tyrosine kinases widely distributed through numerous tissues48 can be reasonably
expected to have off-target, potentially deleterious, effects. Moreover, metabolism of this
molecule necessitates twice daily intraperitoneal or intravenous dosing, which makes
therapeutic use decidedly impractical.

The vehicle: tethered biodegradable microparticles
Controlled release is a powerful method for delivering therapeutic concentrations
of biologically active agents directly to the site of their activity by the degradation of or
elution from a bulk material, or carrier, placed proximate to that target site50. Synthetic
biodegradable polymers including the two polymers used in the construction of the
TEVG scaffold mentioned previously have been used extensively as controlled release
carriers51. Micro- and nano-sized synthetic polymer particles are a particularly attractive
carrier technology from a design perspective because the fabrication process can be finely
controlled to tune the release profile of the therapeutic agent contained within; moreover,
such particles can be functionalized with various surface moieties, such avidin, that
facilitate particle conjugation with biologically active or functionally useful molecules 52.
However, particles are free floating spheres that may be detached from a surface
and thus leave the target site. If particles are to be used form sustained deliver, especially
in a high-shear environment such as the lumen of a vascular graft, they would need to be
tethered in place.
Coatings of poly-L-lysine conjugated to various targeting molecules have been
used to enhance tumor and immunocyte uptake of polymer nanoparticles53,54. The
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positively charged polyamine group of poly-L-lysine interacts adhesively with the partial
negative functional groups of other polymers including as the polyester groups of the
poly(glycolic acid) (PGA) and poly((caprolactone-lactic acid) (PCLA) polymer
constituents of the TEVG scaffold. The weak hydrostatic and van der Waals forces
underlying this adhesion are duplicated over a substantial surface area at the interface of
the these polymers, collectively enabling a strong connection between the TEVG
scaffold, the linker polymer, and SB-431542-eluting particles.

Statement of purpose
This thesis is an application of biomedical engineering principles and techniques
with the above accrued understanding of the pathophysiology of our novel treatment for
hypoplastic left heart syndrome for the purpose of developing of the next generation
tissue engineered vascular graft. Informed biologic direction of TEVG growth and
development in situ might enhance graft performance and permit earlier graft use,
perhaps even single stage palliative surgery, with further improvements in outcome for
this patient population. Understanding of the role of endothelial mesenchymal transition
in vascular neotissue formation is expected to yield far wider-ranging applications to the
treatment of vascular disease – cardiac and peripheral, pediatric and adult, congenital and
acquired.
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Hypothesis
Inhibition of TGF-βR1 by local delivery of SB-431542 is superior to systemic
administration of SB-431542 in the prevention of EndMT-mediated neointimal
hyperplastic stenosis of a TEVG during the critical period for graft failure in a mouse
model.

Specific aims
1. Develop multiplexed hybrid drug release platform for delivery of small molecule
and/or protein species from previously investigated TEVG scaffold
a. Encapsulate candidate therapeutics in release vehicle
b. Tether release vehicle to TEVG scaffold to minimize loss of release
vehicle and off target delivery of therapeutic agent
c. Optimize loading of TEVG scaffold with release vehicle
d. Characterize release of therapeutics from scaffold
e. Confirm therapeutics encapsulated in delivery platform retain bioactivity
2. Validate clinical utility of local versus systemic delivery of SB-431542 in the
prevention of TEVG neointimal hyperplastic stenosis in a small animal model
a. Demonstrate local delivery of SB-431542 is more efficacious than
systemic delivery of SB-431542
b. Demonstrate local delivery of SB-431542 is more economical than
systemic delivery of SB-431542
c. Show efficacy of inhibition of TGF-βR1 signaling by SB-431542 is
dependent upon the release profile of SB-431542
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3. Explore TGF-β1 signaling in EndMT and TEVG neointimal hyperplastic stenosis
a. Validate previous findings that systemic SB-431542 therapeutically
prevents EndMT by replicating results with local delivery
b. Investigate possible disparate effects of delivery of rhTGF-β1 versus SB431542 on TEVG formation and clinical function in a small animal model

Methods
All procedures and methods described in this section were developed and
performed by the author unless otherwise stated. All figures, photographs, and schematics
are original unless otherwise stated.

Scaffold fabrication
TEVG scaffolds were constructed from a nonwoven polyglycolic acid (PGA)
mesh (Concordia Fibers) and a co-polymer sealant solution of poly-L-lactide and –εcaprolactone (P(CL/LA)) as previously described55. Briefly, tubular scaffolds were
formed by compressing a 6.0 mm x 6.0 mm sheet of nonwoven P(CL/LA) felt between a
21-gauge stainless steel rod (to maintain the inner lumen) and a cylindrical cored-out
polypropylene rod. The polymeric scaffolds were coated with a 50:50 copolymer sealant
solution of poly– -caprolactone-l-lactide (263,800 Da; Absorbable Polymers
International, Birmingham, Ala) dissolved at 5% wt/vol in dioxane. Scaffolds were snap
frozen at −20°C for 30 minutes lyophilized overnight to remove solvent.
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SB-431542-eluting scaffold fabrication
SB-431542-eluting PGA-P(CL/LA) scaffolds were fabricated as above except for
the substitution of 5% w/v P(CL/LA) with a 5% w/v P(CL/LA) solution containing 3
mg/ml SB-431542 dissolved in dioxane. The quantity of SB-431542 per scaffold was
derived from a density balance calculation such that each scaffold would contain 1/1000
the cumulative mass of intraperitoneal SB-431542 administered as intraperitoneal
injections into C57L/B6 over two weeks. Scaffolds were stored at -20°C.

Microparticle synthesis

Figure 5. Schematic representation of microparticle synthesis by encapsulation of rhTGFβ1 or SB-431542 in avidin-coated PLGA.

SB-431542 (Sigma-Aldrich Cat. No. S4317) was encapsulated in avidin-coated
PLGA microparticles using a modified oil/water single emulsion technique as previously
described52,56. Briefly, 5 mg of drug and 100 mg PGLA (50/50 monomer ratio, Durect
Corp. Cat. No. B0610-2) dissolved in 2 ml chloroform and 200 ul DMSO were added
dropwise with vortexing to 4 mL of aqueous surfactant solution containing 2.5 mg/mL
polyvinyl alcohol (PVA) (Sigma-Aldrich Cat. No. 363138) and 2.5 mg/mL
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avidin−palmitate bioconjugate to create an emulsion containing microsized droplets of
polymer/solvent, encapsulated SB-431542 and surfactant. Solvent was removed by
magnetic stirring at 20C; hardened microparticles were then washed 3× in DI water and
lyophilized for long-term storage at -20C. Null vehicle control avidin-coated PLGA
microparticles were synthesized as above without SB-431542.
Recombinant human TGF-β1 (rhTGF-β1) expressed in HEK 293 cells
(Humakine, Sigma-Aldrich Cat. No. 8541) was encapsulated in avidin-coated PLGA
microparticles using an water/oil/water emulsion technique. 1.0 ug rhTGF-β1 in PBS was
encapsulated in 5 mg PLGA microparticles per above. Calculations considering prior
studies demonstrating based on 0.2% efficiency of encapsulation of similar hydrophilic
protein leukocyte inhibitor factor in this particle system57 and the relative receptor
affinity, dissociation constants, and mass comparisons approximating a five-fold lower
order of magnitude difference of physiologically active concentrations of SB- rhTGF-β1
(~1.3 pg/ml).

Microparticle characterization
Microparticle size and morphology were analyzed via scanning electron
microscopy (SEM). Samples were sputter-coated with gold under vacuum in an argon
atmosphere using a sputter current of 40 mA (Dynavac Mini Coater, Dynavac, USA).
SEM analysis was carried out with a Philips XL30 SEM using a LaB electron gun with
an accelerating voltage of 10 kV.
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Preparation of adhesive peptide tether

Figure 6. Poly-L-lysine-LC-LC-biotin.

Poly-L-lysine-LC-LC-biotin (pLLB) was synthesized and used as an adhesive
peptide tether to enhance loading of PGA-P(CL/LA) scaffolds with avidin-coated
microparticles. 1.66 mg EZ-Link sulfo NHS-LC-LC-biotin was reacted with 10 ml of a
0.1 mg/ml solution of poly-L-lysine (MW 70,000-150,000, Sigma-Aldritch Cat. No.
P4707 ) in 1x PBS for 2 hours at 4C, dialyzed in 1x PBS for 72 hours, and stored at 4C.

Loading of TEVG scaffolds with release vehicle

Figure 7. Schematic representation of microparticle decoration of TEVG scaffold.

Nonspecific adsorption of avidin-coated PLGA microparticles to PGA-P(CL/LA)
scaffolds not treated with pLLB was titrated by incubating scaffolds trimmed to 5 mm in
axial length with 1 ml of 1, 5, or 10 mg/ml of microparticles in 1x PBS for 10, 30 or 60
minutes. Particle-loaded TEVG scaffolds were immediately snap frozen in liquid
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nitrogen and lyophilized for 6 hours before imaging. Scaffold loading efficiency was
determined with ImageJ software (Image Processing and Analysis in Java, National
Institute of Health, Bethesda, MD) from three SEM images per scaffold cross section,
inner surface, and outer surface by calculating the mean surface density of particles. The
effect of scaffold pretreatment with pLLB on scaffold loading efficiency was assessed
from particle loading density as above after PGA-P(CL/LA) scaffolds were incubated
with 1 ml of 0.01, 0.1 or 1 mg/ml pLLB for 60 minutes on a rotary shaker, washed 3
times with dH2O, incubated with 1 ml 5 mg/ml avidin-coated PLGA microparticles on a
rotary shaker, washed 3 times with dH2O, snap frozen in liquid nitrogen, lyophilized for 6
hours, and imaged by SEM. For in vitro and in vivo studies, PGA-P(CL/LA) scaffolds
were incubated with pLLB for 30 minutes at 20C on a rotary shaker, washed 3 times with
dH2O, incubated with 5 mg/ml empty or SB-431542-eluting avidin-coated PLGA
microparticles for 30 minutes on a rotary shaker, washed 3 times with dH2O, snap frozen
in liquid nitrogen, and lyophilized for 6 hours before storage in a dessicator.

Characterization of SB-431542 release from microparticles and scaffolds
Total encapsulation was approximated as the amount of SB-431542 released over
a 14 day period. Percent encapsulation efficiency was calculated as total encapsulation
divided by maximum theoretical encapsulation. 5 mg of avidin-coated PLGA
microparticles containing SB-431542, PGA-P(CL/LA) scaffolds trimmed to 5 mm axial
length and treated with pLLB and SB-431542-eluting microparticles as above, and SB431542-eluting PGA-P(CL/LA) scaffolds trimmed to 5 mm axial length were incubated
with 400 μl 1x PBS in 2 ml microcentrifuge tubes in triplicate on a rotary shaker at 37C.
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Samples were removed at time points of 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 168, 240,
and 336 hours and centrifuged at 13200 RPM for 10 ten minutes. 300 μl of supernatant
was drawn and replaced with 300 μl 1x PBS. Concentration of SB-431542 in supernatant
diluted with 600 μl 1x PB was determined by spectrophotometry at 320 nm in a quartz
cuvette.

Bioactivity of encapsulated SB-431542by p-SMAD immunoblot
SB-431542 was released into 1 ml 1x PBS from 10 mg avidin-coated PLGA
microparticles and one untrimmed SB-431542-eluting PGA-P(CL/LA) scaffold in 2 ml
microcentrifuge tubes on a rotary shaker at 37C. At 48 hours, samples were centrifuged at
13200 RPM for 10 ten minutes, supernatants were collected and analyzed by
spectrophotometry at 320 nm. SB-431542 concentrations were adjusted to 10 μM by
dilution with 1x PBS. 3T3 human fibroblasts (Sigma Aldrich, Cat. No. 93061524-1VL)
were plated at 500,000/well on a 6-well plate and stimulated at confluence with 700 ul 10
μM SB-431542 in PBS eluted from particles or scaffolds, a stock solution of 10 or 1 μM
SB-431542 containing <1% DMSO, 1 or 1x PBS. After 30 minutes at 37C, cells were
washed with warm PBS and stimulated with 200 ul 2 ng/ml recombinant human TGF-β1
(BD Biosciences, Cat. No. 354039) for 1 hour at 37C. Cells were lysed with ice cold
RIPA lysis buffer containing phosphatase and proteinase inhibitors (PhosSTOP and
cOmplete mini, Roche Applied Science, Cat. No. 04906845001 and 04693116001). Cell
lysates were collected in 200 μl ice cold 1x PBS by scraping, vortexed for 15 seconds,
agitated on a rotary shaker at 4C for 30 minutes, and centrifuged at 12000 RPM for 15
minutes at 4C. Supernatant protein concentrations were determined by DC protein assay
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(Bio-Rad Life Science, Hercules, CA) and protein samples were separated by gel
electrophoresis with a 12% polyacrylamide gel. Samples were transferred to a PVDF
membrane, blocked with 5% milk, and probed with primary rabbit monoclonal antibody
against phosphorylated SMAD-2 (ser426/ser428, Cell Signaling Technology, Cat . No.
3010) and secondary goat anti-rabbit IgG (Cell Signaling Technology, Cat. No. 7074).
The gel was stripped in stripping buffer (50 ml 62.5 mM Tris-HCl, 2% SDS, 100 mM βmercaptoethanol) for 40 minutes at 50C with agitation and reprobed with anti-SMAD2/3
as a loading control. The proteins were visualized with ECL exposure on HyBlot x-ray
film. Cell culture and blots were performed by Joseph T. Patterson and Muriel Cleary,
MD.

Mixed splenocyte scaffold culture
All animal experiments were done in accordance with the institutional guidelines
for the use and care of animals as set by the Institutional Animal Care and Use
Committee (protocol no. 2007-11160 and 2010-11139]). TEVG scaffolds were trimmed
to 5 mm axial length and sterilized under UV light. A 24 well plate was pretreated with
2.5 μg/well anti-CD3 (Sigma Aldrich, Cat. No. SAB4700050). Mixed splenocytes were
collected from a 6 week old Foxp3-GFP C57L/B6 mouse (Jackson Laboratory, Bar
Harbor, ME), plated at 106 cells/well and stimulated with 2.5 ug/well anti-CD28 (Sigma
Aldrich, Cat. No. SAB1405583). One PGA-P(CL/LA) TEVG scaffold, one PGAP(CL/LA) TEVG scaffold treated with pLLB and avidin-coated PGLA microparticles,
one PGA-P(CL/LA) TEVG scaffold treated with pLLB and SB-431542 releasing avidincoated PGLA microparticles, or one PGA-P(CL/LA) TEVG releasing SB-431542 from
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the P(CL/LA) phase were incubated with 1 ml stimulated splenocytes for 4 days in
quadruplicate. Cell proliferation was assessed by cell titer blue assay. IL-2, IL-10, IL-12,
TGF-β, TNF-α, and INF-γ in supernatant were quantified by ELISA. Cells were stained
for CD4 on Pacific Blue, CD8 on r-phycoerythrn, and CD25 on on r-phycoerythrn Cy-7.
Cell populations were assessed by flow cytometry (LSRII, BD Biosciences).

Pre-implantation scaffold processing
Scaffolds were retrieved from -20°C and lyophilized overnight. Scaffolds were
coated with fibrin and thrombin. Scaffolds were sterilized at room temperature under UV
light prior to implantation. Scaffolds used for in vitro release studies were not coated with
fibrin or thrombin.

Implantation of TEVG scaffolds in C57BL/6 mice
All animal experiments were done in accordance with Yale institutional
guidelines for the use and care of animals, and the institutional review board approved all
experimental procedures. All animals were housed and cared for in Yale YARC facilities
in accordance with institutional policy. Experiments were performed as described in
approved IACUC protocol #2010-10835.
TEVG scaffolds were implanted into the infrarenal inferior vena cava (IVC) of 810 week old, female mice as previously described 55. Briefly, female C57BL/6 mice (6-8
wk old, Jackson Laboratory, Bar Harbor, ME) were anesthetized with intraperitoneal
injections of ketamine (100 mg/kg) (Hospira, Inc, Lake Forest, Ill) and xylazine (10
mg/kg) (Ben Venue Laboratories, Bedford, Ohio). After preparation and sterilization of
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the abdomen with betadine and alcohol, a midline laparotomy incision was made. The
IVC was identified and exposed using an 18× dissecting microscope (Zeiss, Thornwood,
NY), and the abdominal cavity bathed in heparinized solution (250 U/mL) (Baxter,
Deerfield, Ill). Control of the IVC was obtained just inferior to the renal veins and
superior to the iliac veins. 10 TEVG scaffolds functionalized with avidin-coated PLGA
microparticles, 10 TEVG scaffolds functionalized with SB-431542-eluting avidin-coated
PLGA microparticles, and 10 TEVG scaffolds withSB-431542 in the P(CL/LA) phase
fabricated as above were implanted as infrarenal IVC interposition grafts via
microsurgical techniques. All anastomoses were preformed in an end-to-end technique
using 10-0 monofilament nylon sutures (Sharpoint Lab Sutures, Calgary, Alberta,
Canada) in interrupted stitches. Adequate hemostasis was achieved before closing the
abdominal cavity. Graft recipients were recovered from surgery on warmed pads and
evaluated for evidence of hind limb ischemia, paralysis, or acute graft thrombosis before
being returned to their cages. All mice were maintained postoperatively without the use
of any anticoagulation or antiplatelet therapy. Surgical implantation of all TEVG
scaffolds was performed by a single fellowship-trained microsurgeon, Tai Yi, MD.

Explantation and tissue preparation
Mice were sacrificed according to Yale IACUC policy and Infrarenal TEVG IVC
grafts were explanted with adjacent tissue by Tai Yi, MD. Explanted grafts were pressure
fixed in 10% formalin overnight and embedded in paraffin. Representative grafts (n = 5)
from each of the 4 study groups were explanted at 2 weeks and evaluated histologically
and by immunohistochemistry. The grafts were pressure perfused before a 24-hour
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fixation in 10% formalin as previously described58. After fixation, grafts were washed
with 1× phosphate-buffered saline and placed in 70% alcohol for an additional 24 hours.

Morphometric analysis
Graft luminal diameters were measured using Image J software. Stenosis was
defined as greater than 50% decrease in luminal diameter. Graft occlusion was defined as
100% narrowing of the luminal diameter. TGF-β positive cell area was measured using
ImageJ software. Two separate sections of each explant were counterstained with
hematoxalin and Gomori trichrome and imaged at 400X magnification.

Histologic analysis
Histologic processing and staining were performed by staff of the Bone Histology
Laboratory, Department of Orthopaedics and Rehabilitation, Yale University School of
Medicine. Grafts were embedded in paraffin and mounted onto slides (5-μm cuts)
allowing for graft analysis. Cellularity and morphometry were evaluated by H&E staining
(Sigma). Collagen was identified using Gomori's trichrome stain (Gomori One-Step
Trichrome Stain, Dako). Lumen diameter was calculated from Gomori trichrome and
H&E-stained sections using Image J software. Further characterization of graft and
neovessel cellular composition was conducted using immunohistochemical techniques.
Von Willebrand Factor (vWF antibody; Abcam) was used to identify luminal endothelial
cells, smooth muscle cells were identified by calponin expression(Calponin antibody;
Abcam), and macrophages were detected using F4/80 (BD Biosciences, San Jose, CA).
Antibody binding was detected using appropriate biotinylated secondary antibodies,
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followed by binding of streptavidin-horseradish peroxidase (HRP) and color development
with 3,3-diaminobenzidine (Vector, Peterborough, United Kingdom). Nuclei were
counterstained with hematoxylin.

Immunohistochemistry
Primary antibodies included: calponin, clone hCP (Sigma), CD31 (Abcam),
smooth muscle α-actin (Dako), vWF (Dako), VE-cadherin (Santa Cruz). Antibody
binding was detected using appropriate biotinylated secondary antibodies, followed by
binding of streptavidin-HRP and color development with 3,3-diaminobenzidine (Vector).
Nuclei were counterstained with hematoxylin.
For immunofluorescence, Two separate sections of each explant underwent triple
immunofluorescent staining with DAPI, SMA, and CD31. Goat-anti-rabbit IgG-Alexa
Fluor 568 (Invitrogen) or goat-anti-mouse IgG-Alexa Fluor 488 (Invitrogen) was used
with subsequent 4',6-diamidino-2-phenylindole nuclear counterstaining.
Immunofluorescence was detected using a Leica SP5 confocal microscope.
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Cost-effectiveness analysis
Comparison of local and systemic delivery strategies was performed using
calculated total multiplicative encapsulation efficiency for each delivery route and current
market pricing of $120 per 5 mg SB-431542.

Statistical analysis
Two-tailed paired Student’s t-test with the assumption of unequal sample variance
was used to compare diameters of the various microparticle species as well as luminal
diameters between the different TEVG scaffold groups after explantation. Two-tailed
Fisher’s exact test was used to compare rates of occlusion between the different TEVG
scaffold groups after explantation.
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Results
Scaffold characterization

Figure 8. Scanning electron micrograph of tubular PGA-PCLA TEVG scaffold in cross
section (A) demonstrating internal and external surfaces available for particle loading and
(B) PGA fiber core overlaid with PCLA polymer web.

Microparticle characterization

Figure 9. Scanning electron micrographs of lyophilized avidin-coated PLGA
microparticles encapsulating (A) null control vehicle, (B) 5 mg SB-431542/100 mg
PLGA, and (C) 1 ug rhTGF-β1.
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Figure 10. No significant differences in (A) mean diameter (p=0.99) or (B) diameter
frequency distribution (p=0.99) of lyophilized avidin-coated PLGA microparticles.

Loading of TEVG scaffolds with release vehicle

Figure 11. Scanning electron micrograph of tubular PGA-PCLA TEVG scaffold (A)
internal and (B) external surfaces after washing demonstrating decoration of TEVG
scaffold with poly-L-lysine-biotin and null vehicle microparticles.
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Figure 13. Poly-L-lysine-biotin linker peptide enhances loading density of internal and
external TEVG scaffold surfaces with null vehicle avidin-coated PLGA microparticles in
a concentration-dependent manner.
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SB-431542-elution studies
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Figure 14. Near-UV spectral photoabsorptivity profile of SB-431542 in PBS
demonstrating absorbance maximum at 320 nm.

Absorbance

2

2

y = 60.842x
R² = 0.9993

1.5
1

1.5

y = 60.004x
R² = 1

1

0.5

0.5

0

0
0

0.01
0.02
Concentration mg/ml

0.03

0

0.01
0.02
Concentration mg/ml

0.03
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Figure 16. (A) Absolute and (B) fractional release of SB-431542 from eluting scaffolds
and from non-eluting scaffolds decorated with eluting PLGA microparticles.
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Figure 17. Western blot demonstrating bioactivity of SB-431542 released from scaffolds
and microparticles by reduced phosphorylation of Smad3 normalized to Smad2/3. Stock
concentrations of SB-431542 and PBS are controls.
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SB-431542 delivery systems exert bioactive effects in mixed splenocyte cell culture
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Figure 18. (A) Cell titer blue and (B) ELISA assays demonstrate that SB-431542 eluted
from microparticles or scaffolds reduces cell viability and influences expression of
cytokines IL-2, IL-10, INF-β, and TGF-β when co-cultured with mixed c57b/l6 mouse
splenocytes.
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SB-431542 or rhTGF-β1 delivery improves TEVG patency in mouse model

Table 1. Morphometry of TEVGs explanted at 2 weeks
TEVG scaffold

N Lumen diameter (mm)

Patency

Patent grafts All grafts
PGA-PCLA [historical control22]

25 0.72 ± 0.09

0.37 ± 0.28

36%

PGA-PCLA(SB-431542)

25 0.72 ± 0.06

0.52 ± 0.32

70%

PGA-PCLA + systemic SB-43154238

16 0.73 ± 0.06

0.67 ± 0.16

88%

PGA-PCLA-biotin/avidin-PLGA [control]

10 0.70 ± 0.07

0.34 ± 0.31

30%

PGA-PCLA-biotin/avidin-PLGA(SB-431542) 10 0.73 ± 0.08

0.73 ± 0.08

100%

PGA-PCLA-biotin/avidin-PLGA(rhTGF-β1)

0.76 ± 0.09

100%

p = 0.203

0.9
Lumen diameter (mm)

0.8
0.7
0.6

0.5
0.4
0.3
0.2
0.1
0

10 0.76 ± 0.09

p = 0.003**

p = 0.427

p = 1.000
p = 0.002**
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Figure 19. Local delivery of SB-431542 by microparticle or scaffold encapsulation as
well as local delivery of rhTGF-β1 by microparticle encapsulation prevent critical
stenosis of a tissue engineered vascular graft during the first two weeks after implantation
as infrarenal inferior vena cava interposition graft compared with nontherapeutic
controls. (A) Luminal diameters are significantly greater with microparticle delivery of
SB-431542 or rhTGF-β1 compared to nontherapeuetic controls or scaffolds
encapsulation. (B) TEVG occlusion is significantly less common in the first two weeks
with local delivery of SB-431542 or rhTGF-β1 by any vehicle, and is not observed with
microparticle delivery of SB-431542 or rhTGF-β1.
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SB-431542 or rhTGF-β1 delivery inhibits neointimal stenosis and does not disrupt
neovessel formation

Figure 20. Local delivery of SB-431542 or rhTGF-β1 prevents both mild and critical
stenosis of a small diameter TEVG IVC graft by hyperplastic smooth muscle
proliferation during the critical first two weeks in vivo. Explanted graft sections
demonstrated complete concentric layers of endothelium (CD31, red), smooth muscle
(SMA, green), and macrophages (F4/80, figure 21). (A) Patent SB-431542 microparticle
TEVG, (B) patent SB-431542 dioxane TEVG, (C) critically stenosis SB-431542 dioxane
TEVG, (D) critically stenosis control TEVG. Blue is DAPI stain for cell nuclei.
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Figure 21. Representative cross sections of explanted occluded SB-431542 eluting TEVG
and patent microparticle TEVG demonstrate paucity of macrophage infiltration (F4/80)
and high density of collagen (Gomori trichrome) and smooth muscle (calponin) in the
hyperplastic luminal obstruction by immunochemical histology. Smooth muscle
infiltration and collagen deposition was the sole observed histologic mechanism of
TEVG failure. Neither thrombotic nor or embolic occlusion were observed.
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Table 2. Comparison of SB-431542 delivery modalities
Delivery route

Local

Systemic

Delivery vehicle

PGA-PCLA(SB-

PGA-PCLA-biotin/avidin- Intraperitoneal

431542)

PLGA(SB-431542)

injection38

Dosing

once

once

10 mg/kg BID IP

Total

1

1

28

100 ug

250 ug

5.6 mg

21.7%

0.51%

100%

13.6 ng

1.26 ng

5.6 mg

$2.4

$6

$134

administrations
Total SB-431542
consumed per
treatment
Encapsulation
efficiency
Total SB-431542
delivered per
treatment
Cost of SB-431542
per treatment
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Discussion
The results above chronicle the development and validation of a platform for local
delivery of therapeutics from a small diameter tissue engineered vascular graft. This
thesis is a proof-of-concept that targeted delivery of therapeutics – one small molecule
receptor tyrosine kinase inhibitor and one recombinant protein – can be built into a
vascular graft and slowly released to control the development and performance of that
graft for weeks after surgical implantation. We have also successfully demonstrated that
this approach is a viable strategy to enhance the clinical utility of our biologic medical
device.
Moreover, the above data document the application of this platform for scientific
discovery. I lead the development of this drug delivery system (specific aim 1) to aid
Yale School of Medicine alumnus Daniel R. Duncan and our colleagues in the Breuer
and Simons labs in validating Dr. Duncan’s investigations of the endothelialmesenchymal transition we observed to underlie stenosis/occlusion of IVC interposition
TEVGs in our small and large animal models. Local delivery of SB-431542 from TEVG
scaffolds and from microparticles tethered to TEVG scaffolds provided strong supporting
evidence that the hyperplastic smooth muscle infiltration of the graft lumens was a TGFβ-mediated process, one that could be intervened upon without the using of seeded cells,
and that was not critical for TEVG formation. Application of this system has advanced
our understanding of TEVG development in vivo and suggested a more complex role for
TGF-β signaling in TEVG formation and behavior in vivo than previously thought.
We can reject the null hypothesis that local delivery of SB-431542 is noninferior
to systemic administration of SB-431542 in the prevention of EndMT-mediated
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neointimal hyperplastic stenosis of a TEVG during the critical period for graft failure in a
mouse model. However, a demonstration of superior efficacy (specific aim 2a) was not
achieved: local delivery of SB-431542 was not significantly more effective than systemic
delivery of SB-431542 in the prevention of TEVG neointimal hyperplastic stenosis.
There was no significant difference in luminal diameters (0.67 ± 0.16 vs 0.73 ± 0.06 mm,
p = 0.871) or patency rates (87.5% vs 100%, p = 0.508) between systemic intraperitoneal
injections of SB-431542 in DMSO vs. microparticle delivery of SB-431542; similar
nonsignificant differences were obtained comparing systemic to local elution of SB431542 from scaffolds. All methods of delivering SB-431542 prevented EndMT and
neointimal hyperplastic critical stenosis of the TEVG to some degree (specific aim 3a).
Failure occurred exclusively by stenosis with luminal proliferation of SMA+ cells.
Disruption of p-Smad signaling by local delivery of SB-431542 prevented this mode of
failure, consistent with inhibition of endothelial-mesenchymal transition and smooth
muscle proliferation. These experiments were powered to demonstrate feasibility and
noninferiority of local versus systemic delivery; the findings obtained support those
hypotheses.
A rudimentary cost analysis and review of the methods weakly suggest that local
delivery of SB-431542 is more economical than systemic delivery of SB-431542
(specific aim 2B). Local delivery of SB-431542 by drug-eluting scaffolds or scaffoldbound microparticle is roughly an order of magnitude cheaper in material costs and
requires considerably less labor, time, and continuing care than serial injections.
Microparticle encapsulation is the least efficient (0.51% encapsulation efficiency) in
terms of material consumption but also the most effective means of maximizing TEVG
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patency in the critical period. Therapeutic administration from the scaffold by either
route, which requires no additional preimplantation processing on the day of surgery or
additional operative steps and also has less onerous postsurgical care requirements, is
inarguable more practical for both care providers and the recipient.
Release studies demonstrated that the eluted SB-431542 was approximately 1/300
the cumulative systemic dose of SB-431542 delivered intraperitoneally, and that 55% of
this dose was delivered during the first day. SB-431542 encapsulated in the TEVG
scaffolds is likely eluted in two peaks: an early bolus that occurs mostly over the first day
post-implantation followed by a gradual release until a second bolus occurs when bulk
hydrolysis completes the PGA-PCLA scaffold. Conversely, microparticles tethered to the
scaffold delivered a cumulative SB-431542 dose one order of magnitude lower nearly
linearly over the first week. The sustained release was significantly more efficacious in
achieving the primary outcome of maximum graft patency at two weeks (specific aim
2c). The capability and utility of this system for multiplexed and asymmetric drug
delivery from multiple particle species tethered to the scaffold with or without concurrent
release from the scaffold polymer remain to be explored.
The investigation of the effect and mechanism of rhTGF-β1 on TEVG formation
and function (specific aim 3b) remains incomplete and inconclusive. The core experiment
of local rhTGF-β1delivery in the same mouse model was completed and generated the
very unexpected and interesting result of also achieving 100% TEVG patency.
Unfortunately, the clinical obligations of medical school and the departure of the Breuer
lab from Yale University prevented me from completing the necessary experiments to
validate those findings. Bioactivity and the release profile of aqueous rhTGF-β1 eluted
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from microparticles were never assessed: no data exist to demonstrate that rhTGF-β1 was
actually eluted from the encapsulating particles, that any eluted rhTGF-β1 retained
physiologic activity, or that rhTGF-β1 was delivered to the target site. Therefore, the
unexpected and extremely desirable results obtained with rhTGF-β1-eluting scaffolds
should not be accepted.
Nonetheless, the only variable altered in that experiment was the inclusion of
rhTGF-β1 in microparticles otherwise identical to those present on the control grafts,
decorated on identical scaffolds, constructed by the same operator from the same
materials, implanted in the same mouse linage by the same surgeon and same technique.
It would seem very possible that rhTGF-β1 was solely responsible for the effect of
significantly lower rate of occlusion (p = 0.003).
This is an unexpected finding, or possible finding as above. I elected to explore
rhTGF-β1 roughly as a control, presuming that if inhibiting the tyrosine kinase of the
TGF-βR1/R2 receptors with SB-431542 improved patency then perhaps supplying the
agonist would have an opposite, clinically deleterious effect – perhaps increasing smooth
muscle hyplerplasia, potentially through EndMT, decreasing patency rates, and degrading
clinical utility. Morphologic and immunohistochemical analyses of the explanted rhTGFβ1 TEVGs do not provide suggestions as to why the opposite outcome was observed;
histologic architecture is not grossly different from patent TEVGs with or without SB431542 treatment and cell phenotype densities are not significantly different.
The possibility that rhTGF-β1 may have had a therapeutic effect similar to an
antagonist of a mediator of a TGF-β1 signaling pathway suggests that the number ofTGFβ signaling players involved in EndMT and complexity of their relationships may be
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greater than we appreciated. Indeed, TGF-β-mediated inhibition of smooth muscle
proliferation independent of ALK5/TGFβR1 signaling or ALK signaling altogether.
Exploration of these prospects was to be the focus of the “fifth year” research year I
ultimately did embark upon.

Future directions
The next step would be to investigate the role of myriad pathways of TGFb
signaling in EnMT and neovessel formation. Perhaps selective kinase inhibition of
ALK1/2/3/6 → p-Smad1/5 by dorsomorphin59,60, ALK4/5/7 → p-Smad2/3 by SB43154248, or both Smad signaling pathways plus ALK1/ALK5 codimer activity by
dorsomorphin and SB-431542 combined administration during TEVG formation would
elucidate the relevance of Smad- and non-Smad dependent TGF-β signaling pathways to
EndMT and long-term TEVG performance. Small molecule inhibitors would be
preferable to protein agonists/antagonists for signaling manipulation in this system as
smaller size, resilience to degradation, and lower cost would facilitate screening studies
and future local delivery from the TEVG scaffold.
Intervention on the most relevant TGF-β pathway(s) might become the foundation
for future strategies to regulate TEVG growth and long-term patency. Endothelial
specific reporter mice generated by crossing Tie2-Cre with R26R-LacZ mice would
allow colocalization of LacZ+ with mesenchymal markers and quantification of EndMT
in harvested TEVG. The effect of systemic administration of each kinase inhibitor or
combination on long term patency, stability, and growth could be assessed by quantifying
EndMT and diameter of the neovessel lumen and wall layers at various time points.
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Local delivery of dorsomorphin and/or SB-431542 from hydrolysable polymer
microparticles tethered to the TEVG scaffold61 would both validate these preliminary
studies and provide a cell-free TEVG scaffold amenable to use as an off-the-shelf
vascular graft34. Scaling up this drug-releasing graft in a lamb model of an extracardiac
Fontan shunt comparable in size to that used in a human child would demonstrate that
TGF-β1 signaling inhibition improves the function of a TEVG suitable for palliation of
hypoplastic left heart syndrome. This would open the door to application for an FDAsanctioned human clinical trial of a cell-free, off-the-shelf, stable, growing TEVG for
patients with hypoplastic left heart syndrome – a major advance over the standard of care.
Given the centrality of TGF-β signaling in embryonic cardiac development,
further understanding of TGF-beta signaling in the tissue engineered vascular graft may
inform tissue engineering of other cardiovascular structures. Notably, the combined
administration SB-431542 and for dorsomorphin as porposed in herein induces the
differentiation of endothelial cells into cardiomyocytes59. Delivery of these kinase
inhibitors from a degradable scaffold may provide the foundation for myocardial patch
design. More globally, I envision drug releasing scaffolds as tissue blueprints that will
underpin the future of the field of tissue engineering. This proposal to explore the
complexity of TGF-β signaling in a TEVG through local and systemic delivery of
agonists and antagonists will become a model for “cell-free,” in-situ tissue engineering
that combines targeted architectural intervention by surgical scaffold implantation with
subsequent tissue building through local-drug-induced cell recruitment and pathway
manipulation.
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